Daily Trades
- Dylan Jovine
This climate of fear is our friend. It has created opportunities in the biotech sector which will look downright silly in three to five years.
- Dylan Jovine
Now the company can aggressively market these drugs to as many as 70 million people.
- Dylan Jovine
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
- Dylan Jovine
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
- Dylan Jovine
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
- Dylan Jovine
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
- Dylan Jovine
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.
deal of the month
Categories
Dylan Jovine | Bull? Bear? Nobody Knows. China Tariffs Spark Volatility and Wall Street Confusion
Dylan Jovine | US Debt Crisis 2025: Why Creditors Are Dumping Treasuries
Dylan Jovine | Why Gold is Soaring While Markets Crash | Worst April Since the Great Depression
Recent posts
Tags
Connect with Us
- Dylan Jovine
This climate of fear is our friend. It has created opportunities in the biotech sector which will look downright silly in three to five years.
- Dylan Jovine
Now the company can aggressively market these drugs to as many as 70 million people.
- Dylan Jovine
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
- Dylan Jovine
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
- Dylan Jovine
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
- Dylan Jovine
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
- Dylan Jovine
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.